<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000367424"><TermName>abarelix</TermName><TermPronunciation>(uh-BAYR-eh-lix)</TermPronunciation><TermDefinition><DefinitionText>A drug used to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available. It belongs to the family of drugs called gonadotropin-releasing hormone (GnRH) antagonists. Also called Plenaxis.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000711583" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;abarelix&quot;" language="en" id="_3"/><MediaLink ref="CDR0000711582" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;abarelix&quot;" language="es" id="_4"/><SpanishTermName>abarelix</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para reducir la cantidad de testosterona que se produce en los pacientes con cáncer de próstata sintomático avanzado para el que  no se dispone de otras opciones de tratamiento. Pertenece a la familia de medicamentos llamados antagonistas de la hormona liberadora de gonadotropina (HLGn). También se llama Plenaxis.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-04-23</DateFirstPublished></GlossaryTerm>
